Boehringer-Ingelheim

In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.  

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

Poor patient health, tumor histology, insufficient tissue samples, and long turnaround times are some reasons doctors gave for not using EGFR status to determine care.

New survival data suggest that patients with del19 mutations should receive Gilotrif as their top option and that researchers should no longer clump different EGFR-mutated subpopulations together in research, lead study investigator Lecia Sequist said.

NEW YORK (GenomeWeb) – IDBS said this week the Boehringer Ingelheim is using IDBS' E-WorkBook Suite to help streamline and improve its research and development efforts.

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network's Oncology Research Program has awarded grants to four researchers who will investigate the efficacy of the drug nintedanib in non-small cell lung, colorectal, and gastrointestinal cancers.

Originally published Sept. 23.

NEW YORK (GenomeWeb News) – Ventana Medical Systems and Boehringer Ingelheim announced today that they will collaborate on the development of companion diagnostic products for cancer drugs in the German drug firm's pipeline.

Pages

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.